{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:55:03Z","timestamp":1768002903889,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02149-3","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T07:01:31Z","timestamp":1743231691000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk of secondary myeloid neoplasms following treatment in patients with grade I\u2013II follicular lymphoma: a retrospective cohort study"],"prefix":"10.1007","volume":"16","author":[{"given":"Yuebo","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"issue":"21","key":"2149_CR1","doi-asserted-by":"publisher","first-page":"4221","DOI":"10.1002\/cncr.31695","volume":"124","author":"KM Kenzik","year":"2018","unstructured":"Kenzik KM, Mehta A, Richman JS, Kilgore M, Bhatia S. Congestive heart failure in older adults diagnosed with follicular lymphoma: a population-based study. Cancer. 2018;124(21):4221\u201330. https:\/\/doi.org\/10.1002\/cncr.31695.","journal-title":"Cancer"},{"issue":"14","key":"2149_CR2","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1182\/blood-2018-08-822148","volume":"133","author":"C Casulo","year":"2019","unstructured":"Casulo C, Barr PM. How I treat early-relapsing follicular lymphoma. Blood. 2019;133(14):1540\u20137. https:\/\/doi.org\/10.1182\/blood-2018-08-822148.","journal-title":"Blood"},{"issue":"6","key":"2149_CR3","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","volume":"122","author":"D Tan","year":"2013","unstructured":"Tan D, Horning SJ, Hoppe RT, Levy R, Rosenberg SA, Sigal BM, et al. Improvements in observed and relative survival in follicular grade 1\u20132 lymphoma during 4 decades: the Stanford University experience. Blood. 2013;122(6):981\u20137. https:\/\/doi.org\/10.1182\/blood-2013-03-491514.","journal-title":"Blood"},{"issue":"18","key":"2149_CR4","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1002\/cncr.29491","volume":"121","author":"JA Vargo","year":"2015","unstructured":"Vargo JA, Gill BS, Balasubramani GK, Beriwal S. What is the optimal management of early-stage low-grade follicular lymphoma in the modern era? Cancer. 2015;121(18):3325\u201334. https:\/\/doi.org\/10.1002\/cncr.29491.","journal-title":"Cancer"},{"key":"2149_CR5","doi-asserted-by":"publisher","unstructured":"Teepen JC, Curtis RE, Dores GM, Berrington de Gonzalez A, van den Heuvel-Eibrink MM, Kremer LCM, et al. Risk of subsequent myeloid neoplasms after radiotherapy treatment for a solid cancer among adults in the United States, 2000\u20132014. Leukemia. 2018;32(12):2580\u20139. https:\/\/doi.org\/10.1038\/s41375-018-0149-2.","DOI":"10.1038\/s41375-018-0149-2"},{"issue":"4","key":"2149_CR6","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/leu.2017.323","volume":"32","author":"RJ Molenaar","year":"2018","unstructured":"Molenaar RJ, Pleyer C, Radivoyevitch T, Sidana S, Godley A, Advani AS, et al. Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine. Leukemia. 2018;32(4):952\u20139. https:\/\/doi.org\/10.1038\/leu.2017.323.","journal-title":"Leukemia"},{"issue":"1\u20132","key":"2149_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cbi.2009.12.013","volume":"184","author":"G Leone","year":"2010","unstructured":"Leone G, Fianchi L, Pagano L, Voso MT. Incidence and susceptibility to therapy-related myeloid neoplasms. Chem Biol Interact. 2010;184(1\u20132):39\u201345. https:\/\/doi.org\/10.1016\/j.cbi.2009.12.013.","journal-title":"Chem Biol Interact"},{"issue":"5","key":"2149_CR8","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1080\/10428194.2019.1711074","volume":"61","author":"Q Wang","year":"2020","unstructured":"Wang Q, Jiang C, Zhang Y, Zhang Y, Yue B, Zheng-Lin B, et al. Cardiovascular mortality among chronic myeloid leukemia patients in the pre-tyrosine kinase inhibitor (TKI) and TKI eras: a surveillance, epidemiology and end results (SEER) analysis. Leuk Lymphoma. 2020;61(5):1147\u201357. https:\/\/doi.org\/10.1080\/10428194.2019.1711074.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2149_CR9","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1001\/jamaoncol.2018.5625","volume":"5","author":"LM Morton","year":"2019","unstructured":"Morton LM, Dores GM, Schonfeld SJ, Linet MS, Sigel BS, Lam CJK, et al. Association of chemotherapy for solid tumors with development of therapy-related myelodysplastic syndrome or acute myeloid leukemia in the modern era. JAMA Oncol. 2019;5(3):318\u201325. https:\/\/doi.org\/10.1001\/jamaoncol.2018.5625.","journal-title":"JAMA Oncol"},{"issue":"8 Suppl","key":"2149_CR10","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/j.jclinepi.2013.01.013","volume":"66","author":"EA Stuart","year":"2013","unstructured":"Stuart EA, Lee BK, Leacy FP. Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research. J Clin Epidemiol. 2013;66(8 Suppl):S84-S90.e1. https:\/\/doi.org\/10.1016\/j.jclinepi.2013.01.013.","journal-title":"J Clin Epidemiol"},{"issue":"21","key":"2149_CR11","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1002\/cncr.34453","volume":"128","author":"H Ha","year":"2022","unstructured":"Ha H, Kim HJ, Park JH, Shin A, Lee KN, Han K, et al. Epidemiologic outlook of therapy-related myeloid neoplasms and selection of high-risk patients: a Korean nationwide study. Cancer. 2022;128(21):3888\u201396. https:\/\/doi.org\/10.1002\/cncr.34453.","journal-title":"Cancer"},{"issue":"15","key":"2149_CR12","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1182\/blood-2012-08-448068","volume":"121","author":"LM Morton","year":"2013","unstructured":"Morton LM, Dores GM, Tucker MA, Kim CJ, Onel K, Gilbert ES, et al. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975\u20132008. Blood. 2013;121(15):2996\u20133004. https:\/\/doi.org\/10.1182\/blood-2012-08-448068.","journal-title":"Blood"},{"issue":"12","key":"2149_CR13","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1200\/jco.18.00605","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, van der Jagt R, Kahl B, Wood P, Hawkins T, MacDonald D, et al. First-line treatment of patients with indolent non-hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol. 2019;37(12):984\u201391. https:\/\/doi.org\/10.1200\/jco.18.00605.","journal-title":"J Clin Oncol"},{"issue":"9","key":"2149_CR14","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1002\/ajh.23772","volume":"89","author":"XQ Xu","year":"2014","unstructured":"Xu XQ, Wang JM, Gao L, Qiu HY, Chen L, Jia L, et al. Characteristics of acute myeloid leukemia with myelodysplasia-related changes: a retrospective analysis in a cohort of Chinese patients. Am J Hematol. 2014;89(9):874\u201381. https:\/\/doi.org\/10.1002\/ajh.23772.","journal-title":"Am J Hematol"},{"issue":"3","key":"2149_CR15","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.stem.2021.01.018","volume":"28","author":"J Tong","year":"2021","unstructured":"Tong J, Sun T, Ma S, Zhao Y, Ju M, Gao Y, et al. Hematopoietic stem cell heterogeneity is linked to the initiation and therapeutic response of myeloproliferative neoplasms. Cell Stem Cell. 2021;28(3):502-13.e6. https:\/\/doi.org\/10.1016\/j.stem.2021.01.018.","journal-title":"Cell Stem Cell"},{"issue":"5","key":"2149_CR16","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/cncr.29096","volume":"121","author":"S Bhatia","year":"2015","unstructured":"Bhatia S. Genetic variation as a modifier of association between therapeutic exposure and subsequent malignant neoplasms in cancer survivors. Cancer. 2015;121(5):648\u201363. https:\/\/doi.org\/10.1002\/cncr.29096.","journal-title":"Cancer"},{"issue":"10","key":"2149_CR17","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1002\/cncr.25067","volume":"116","author":"JD Wright","year":"2010","unstructured":"Wright JD, St Clair CM, Deutsch I, Burke WM, Gorrochurn P, Sun X, et al. Pelvic radiotherapy and the risk of secondary leukemia and multiple myeloma. Cancer. 2010;116(10):2486\u201392. https:\/\/doi.org\/10.1002\/cncr.25067.","journal-title":"Cancer"},{"issue":"6","key":"2149_CR18","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1097\/CCO.0b013e32834bcc2a","volume":"23","author":"G Leone","year":"2011","unstructured":"Leone G, Fianchi L, Voso MT. Therapy-related myeloid neoplasms. Curr Opin Oncol. 2011;23(6):672\u201380. https:\/\/doi.org\/10.1097\/CCO.0b013e32834bcc2a.","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"2149_CR19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/leu.2015.258","volume":"30","author":"T Radivoyevitch","year":"2016","unstructured":"Radivoyevitch T, Sachs RK, Gale RP, Molenaar RJ, Brenner DJ, Hill BT, et al. Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation. Leukemia. 2016;30(2):285\u201394. https:\/\/doi.org\/10.1038\/leu.2015.258.","journal-title":"Leukemia"},{"issue":"3","key":"2149_CR20","doi-asserted-by":"publisher","first-page":"djt462","DOI":"10.1093\/jnci\/djt462","volume":"106","author":"S Mukherjee","year":"2014","unstructured":"Mukherjee S, Reddy CA, Ciezki JP, Abdel-Wahab M, Tiu RV, Copelan E, et al. Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation. J Natl Cancer Inst. 2014;106(3):djt462. https:\/\/doi.org\/10.1093\/jnci\/djt462.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2149_CR21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","volume":"107","author":"LM Morton","year":"2006","unstructured":"Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001. Blood. 2006;107(1):265\u201376. https:\/\/doi.org\/10.1182\/blood-2005-06-2508.","journal-title":"Blood"},{"issue":"3","key":"2149_CR22","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/bjh.14061","volume":"174","author":"SA Srour","year":"2016","unstructured":"Srour SA, Devesa SS, Morton LM, Check DP, Curtis RE, Linet MS, et al. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms in the United States, 2001\u201312. Br J Haematol. 2016;174(3):382\u201396. https:\/\/doi.org\/10.1111\/bjh.14061.","journal-title":"Br J Haematol"},{"issue":"1","key":"2149_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1182\/asheducation-2016.1.24","volume":"2016","author":"M Heuser","year":"2016","unstructured":"Heuser M. Therapy-related myeloid neoplasms: Does knowing the origin help to guide treatment? Hematology Am Soc Hematol Educ Program. 2016;2016(1):24\u201332. https:\/\/doi.org\/10.1182\/asheducation-2016.1.24.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"2149_CR24","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/sj.leu.2405078","volume":"22","author":"J Pedersen-Bjergaard","year":"2008","unstructured":"Pedersen-Bjergaard J, Andersen MK, Andersen MT, Christiansen DH. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2008;22(2):240\u20138. https:\/\/doi.org\/10.1038\/sj.leu.2405078.","journal-title":"Leukemia"},{"issue":"3","key":"2149_CR25","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/hon.3128","volume":"41","author":"S Dote","year":"2023","unstructured":"Dote S, Inose R, Goto R, Kobayashi Y, Muraki Y. Risk of a second cancer and infection in patients with indolent B-cell lymphoma exposed to first-line bendamustine plus rituximab: a retrospective analysis of an administrative claims database. Hematol Oncol. 2023;41(3):354\u201362. https:\/\/doi.org\/10.1002\/hon.3128.","journal-title":"Hematol Oncol"},{"issue":"4","key":"2149_CR26","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1080\/01480545.2018.1458236","volume":"42","author":"TS Pereira","year":"2019","unstructured":"Pereira TS, Sant\u2019anna JR, Morais JF, Yajima J, Mathias PCF, Franco C, et al. Assessment of bendamustine-induced genotoxicity in eukaryotic cells. Drug Chem Toxicol. 2019;42(4):394\u2013402. https:\/\/doi.org\/10.1080\/01480545.2018.1458236.","journal-title":"Drug Chem Toxicol"},{"issue":"11","key":"2149_CR27","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1007\/s00277-014-2135-8","volume":"93","author":"R Garc\u00eda Mu\u00f1oz","year":"2014","unstructured":"Garc\u00eda Mu\u00f1oz R, Izquierdo-Gil A, Mu\u00f1oz A, Roldan-Galiacho V, Rabasa P, Panizo C. Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab. Ann Hematol. 2014;93(11):1879\u201387. https:\/\/doi.org\/10.1007\/s00277-014-2135-8.","journal-title":"Ann Hematol"},{"issue":"20","key":"2149_CR28","doi-asserted-by":"publisher","first-page":"4140","DOI":"10.1182\/bloodadvances.2021004964","volume":"5","author":"AA Patel","year":"2021","unstructured":"Patel AA, Rojek AE, Drazer MW, Weiner H, Godley LA, Le Beau MM, et al. Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy. Blood Adv. 2021;5(20):4140\u20138. https:\/\/doi.org\/10.1182\/bloodadvances.2021004964.","journal-title":"Blood Adv"},{"issue":"4","key":"2149_CR29","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1073\/pnas.1015350108","volume":"108","author":"X Cao","year":"2011","unstructured":"Cao X, Wu X, Frassica D, Yu B, Pang L, Xian L, et al. Irradiation induces bone injury by damaging bone marrow microenvironment for stem cells. Proc Natl Acad Sci USA. 2011;108(4):1609\u201314. https:\/\/doi.org\/10.1073\/pnas.1015350108.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2149_CR30","doi-asserted-by":"publisher","DOI":"10.1200\/jco-24-01487","author":"MA Richard","year":"2024","unstructured":"Richard MA, Yan C, Chen Y, Gibson CJ, Kalra R, Bosworth A, et al. Sex-based differences in risk of therapy-related myeloid neoplasms. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/jco-24-01487.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2149_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.beha.2019.02.006","volume":"32","author":"P Desai","year":"2019","unstructured":"Desai P, Roboz GJ. Clonal hematopoiesis and therapy related MDS\/AML. Best Pract Res Clin Haematol. 2019;32(1):13\u201323. https:\/\/doi.org\/10.1016\/j.beha.2019.02.006.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"2149_CR32","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/s1470-2045(16)30627-1","volume":"18","author":"NK Gillis","year":"2017","unstructured":"Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ, et al. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncol. 2017;18(1):112\u201321. https:\/\/doi.org\/10.1016\/s1470-2045(16)30627-1.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2149_CR33","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/s1470-2045(16)30626-x","volume":"18","author":"K Takahashi","year":"2017","unstructured":"Takahashi K, Wang F, Kantarjian H, Doss D, Khanna K, Thompson E, et al. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol. 2017;18(1):100\u201311. https:\/\/doi.org\/10.1016\/s1470-2045(16)30626-x.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2149_CR34","doi-asserted-by":"publisher","first-page":"6025","DOI":"10.1038\/s41467-024-50384-z","volume":"15","author":"EJM Bertrums","year":"2024","unstructured":"Bertrums EJM, de Kanter JK, Derks LLM, Verheul M, Trabut L, van Roosmalen MJ, et al. Selective pressures of platinum compounds shape the evolution of therapy-related myeloid neoplasms. Nat Commun. 2024;15(1):6025. https:\/\/doi.org\/10.1038\/s41467-024-50384-z.","journal-title":"Nat Commun"},{"issue":"7540","key":"2149_CR35","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nature13968","volume":"518","author":"TN Wong","year":"2015","unstructured":"Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature. 2015;518(7540):552\u20135. https:\/\/doi.org\/10.1038\/nature13968.","journal-title":"Nature"},{"issue":"11","key":"2149_CR36","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1001\/jamaoncol.2017.0465","volume":"3","author":"THM Keegan","year":"2017","unstructured":"Keegan THM, Bleyer A, Rosenberg AS, Li Q, Goldfarb M. Second primary malignant neoplasms and survival in adolescent and young adult cancer survivors. JAMA Oncol. 2017;3(11):1554\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0465.","journal-title":"JAMA Oncol"},{"issue":"5","key":"2149_CR37","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s12185-019-02620-2","volume":"109","author":"K Sasaki","year":"2019","unstructured":"Sasaki K, Kantarjian HM, O\u2019Brien S, Ravandi F, Konopleva M, Borthakur G, et al. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Int J Hematol. 2019;109(5):545\u201352. https:\/\/doi.org\/10.1007\/s12185-019-02620-2.","journal-title":"Int J Hematol"},{"key":"2149_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102060","volume":"61","author":"LM Morton","year":"2023","unstructured":"Morton LM, Curtis RE, Linet MS, Schonfeld SJ, Advani PG, Dalal NH, et al. Trends in risk for therapy-related myelodysplastic syndrome\/acute myeloid leukemia after initial chemo\/immunotherapy for common and rare lymphoid neoplasms, 2000\u20132018. EClinicalMedicine. 2023;61: 102060. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102060.","journal-title":"EClinicalMedicine"},{"issue":"8","key":"2149_CR39","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11864-015-0355-3","volume":"16","author":"SB Zeichner","year":"2015","unstructured":"Zeichner SB, Arellano ML. Secondary adult acute myeloid leukemia: a review of our evolving understanding of a complex disease process. Curr Treat Options Oncol. 2015;16(8):37. https:\/\/doi.org\/10.1007\/s11864-015-0355-3.","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"2149_CR40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","volume":"112","author":"DE Rollison","year":"2008","unstructured":"Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001\u20132004, using data from the NAACCR and SEER programs. Blood. 2008;112(1):45\u201352. https:\/\/doi.org\/10.1182\/blood-2008-01-134858.","journal-title":"Blood"},{"issue":"2","key":"2149_CR41","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/cncr.26295","volume":"118","author":"R Jagsi","year":"2012","unstructured":"Jagsi R, Abrahamse P, Hawley ST, Graff JJ, Hamilton AS, Katz SJ. Underascertainment of radiotherapy receipt in surveillance, epidemiology, and end results registry data. Cancer. 2012;118(2):333\u201341. https:\/\/doi.org\/10.1002\/cncr.26295.","journal-title":"Cancer"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02149-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02149-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02149-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T07:01:34Z","timestamp":1743231694000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02149-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2149"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02149-3","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"21 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Since the data were de-identified and available to the public, the current study did not require ethics committee permission. For this type of study, formal consent is not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"397"}}